Research progress on body fluids microRNAs in the diagnosis of cholangiocarcinoma

doi:10.3760/cma.j.issn.1673422X.2017.04.016

Abstract

Abstract: The development of cholangiocarcinoma is slow, but its metastasis is extremely quick. When the tumor is found, the patients often have missed optimal operation period, and there is a lack of effective diagnostic indexes at present. In recent years, with the rapid development of molecular biology, studies find that microRNAs (miRNAs) are closely associated with cholangiocarcinoma. Because of miRNAs have great stability in various types of body fluids, so miRNAs in serum/plasma and bile are expected to become potential biomarkers in the diagnosis of cholangiocarcinoma.

Key words: MicroRNAs, Bile duct neoplasms, Serum, Plasma, Bile, Diagnosis

Zou Rongji, Ma Qingjiu. Research progress on body fluids microRNAs in the diagnosis of cholangiocarcinoma[J]. Journal of International Oncology, 2017, 44(4): 300-303.

References

［1］刘子沛, 郑燕华, 白洁, 等. 多种肿瘤标志物检测在胆管癌诊断中的临床意义［J］. 中华肝胆外科杂志, 2013, 19(9): 657-660. DOI: 10.3760/cma.j.issn.10078118.2013.09.005. ［2］ Hwang J, Kim YK, Park MJ, et al. Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced MRI［J］. J Magn Reson Imaging, 2012, 36(4): 881-889. DOI: 10.1002/jmri.23728. ［3］ Motawi TK, Rizk SM, Ibrahim TM, et al. Circulating microRNAs, miR-92a, miR-100 and miR-143, as non-invasive biomarkers for bladder cancer diagnosis［J］. Cell Biochem Funct, 2016, 34(3): 142-148. DOI: 10.1002/cbf.3171. ［4］ Bertoli G, Cava C, Castiglioni I. MicroRNAs: new biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer［J］. Theranostics, 2015, 5(10): 1122-1143. DOI: 10.7150/thno.11543. ［5］ Braicu C, Cojocneanu-Petric R, Chira S, et al. Clinical and pathological implications of miRNA in bladder cancer［J］. Int J Nanomedicine, 2015, 10: 791-800. DOI: 10.2147/IJN.S72904. ［6］ Fujita Y, Kuwano K, Ochiya T, et al. The impact of extracellular vesicle-encapsulated circulating microRNAs in lung cancer research［J］. Biomed Res Int, 2014, 2014: 486413. DOI: 10.1155/2014/486413. ［7］ Li L, Masica D, Ishida M, et al. Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis［J］. Hepatology, 2014, 60(3): 896-907. DOI: 10.1002/hep.27050. ［8］ Plieskatt J, Rinaldi G, Feng Y, et al. A microRNA profile associated with opisthorchis viverrini-induced cholangiocarcinoma in tissue and plasma［J］. BMC Cancer, 2015, 15: 309. DOI: 10.1186/s12885-015-1270-5. ［9］ Liang Z, Liu X, Zhang Q, et al. Diagnostic value of microRNAs as biomarkers for cholangiocarcinoma［J］. Dig Liver Dis, 2016, 48(10): 1227-1232. DOI: 10.1016/j.dld.2016.07.006. ［10］ Meng F, Henson R, Lang M, et al. Involvement of human microRNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines［J］. Gastroenterology, 2006, 130(7): 2113-2129. DOI: 10.1053/j.gastro.2006.02.057. ［11］ Silakit R, Loilome W, Yongvanit P, et al. Circulating miR-192 in liver fluke-associated cholangiocarcinoma patients: a prospective prognostic indicator［J］. J Hepatobiliary Pancreat Sci, 2014, 21(12): 864-872. DOI: 10.1002/jhbp.145. ［12］彭丰, 王敏, 江建新, 等. 微RNA-200b在胆管癌中的表达及其对癌细胞凋亡与侵袭转移特性的影响［J］. 中华肝胆外科杂志, 2014, 20(2): 123-127. DOI: 10.3760/cma.j.issn.1007-8118.2014.02.012. ［13］ Huang M, Wu X, Cao H, et al. Regulatory role of serum miR-224 in invasiveness and metastasis of cholangiocarcinoma［J］. Zhonghua Gan Zang Bing Za Zhi, 2015, 23(10): 748-753. DOI: 10.3760/cma.j.issn.1007-3418.2015.10.008. ［14］ Kojima M, Sudo H, Kawauchi J, et al. MicroRNA markers for the diagnosis of pancreatic and biliary-tract cancers［J］. PLoS One, 2015, 10(2): e0118220. DOI: 10.1371/journal.pone.0118220. ［15］ Cheng Q, Feng F, Zhu L, et al. Circulating miR-106a is a novel prognostic and lymph node metastasis indicator for cholangiocarcinoma［J］. Sci Rep, 2015, 5: 16103. DOI: 10.1038/srep16103. ［16］ Razumilava N, Gores GJ. Cholangiocarcinoma［J］. Lancet, 2014, 383(9935): 2168-2179. DOI: 10.1016/S0140-6736(13)61903-0. ［17］ Wang S, Yin J, Li T, et al. Upregulated circulating miR-150 is associated with the risk of intrahepatic cholangiocarcinoma［J］. Oncol Rep, 2015, 33(2): 819-825. DOI: 10.3892/or.2014.3641. ［18］ Huang S, Chen Y, Wu W, et al. miR-150 promotes human breast cancer growth and malignant behavior by targeting the pro-apoptotic purinergic P2X7 receptor［J］. PLoS One, 2013, 8(12): e80707. DOI: 10.1371/journal.pone.0080707. ［19］ míd D, Kubaková D, Dole-al J, et al. Predictive and prognostic factors of gastric cancer［J］. Rozhl Chir, 2016, 95(4): 156-161. ［20］ Feng J, Yang Y, Zhang P, et al. miR-150 functions as a tumour suppressor in human colorectal cancer by targeting c-Myb［J］. J Cell Mol Med, 2014, 18(10): 2125-2134. DOI: 10.1111/jcmm.12398. ［21］ Qu Y, Pan S, Kang M, et al. MicroRNA-150 functions as a tumor suppressor in osteosarcoma by targeting IGF2BP1［J］. Tumour Biol, 2016, 37(4): 5275-5284. DOI: 10.1007/s13277-015-4389-8. ［22］ Huang Y, Yang YB, Zhang XH, et al. MicroRNA-21 gene and cancer［J］. Med Oncol, 2013, 30(1): 376. DOI: 10.1007/s12032-012-0376-8. ［23］ Kishimoto T, Eguchi H, Nagano H, et al. Plasma miR-21 is a novel diagnostic biomarker for biliary tract cancer［J］. Cancer Sci, 2013, 104(12): 1626-1631. DOI: 10.1111/cas.12300. ［24］ Correa-Gallego C, Maddalo D, Doussot A, et al. Circulating plasma levels of microRNA-21 and microRNA-221 are potential diagnostic markers for primary intrahepatic cholangiocarcinoma［J］. PLoS One, 11(9): e0163699. DOI: 10.1371/journal.pone.0163699. ［25］ Pasternak A, Szura M, Gil K, et al. Metabolism of bile with respect to etiology of gallstone disease-systematic review［J］. Folia Med Cracov, 2014, 54(2): 5-16. ［26］ Munoz-Garrido P, García-Fernández de Barrena M, Hijona E, et al. MicroRNAs in biliary diseases［J］. World J Gastroenterol, 2012, 18(43): 6189-6196. DOI: 10.3748/wjg.v18.i43.6189. ［27］ Haga H, Yan I, Takahashi K, et al. Emerging insights into the role of microRNAs in the pathogenesis of cholangiocarcinoma［J］. Gene Expr, 2014, 16(2): 93-99. DOI: 10.3727/105221614X13919976902174. ［28］ Shigehara K, Yokomuro S, Ishibashi O, et al. Real-time PCR-based analysis of the human bile microRNAome identifies miR-9 as a potential diagnostic biomarker for biliary tract cancer［J］. PLoS One, 2011, 6(8): e23584. DOI: 10.1371/journal.pone.0023584. ［29］ Voigtl-nder T, Gupta SK, Thum S, et al. MicroRNAs in serum and bile of patients with primary sclerosing cholangitis and/or cholangiocarcinoma［J］. PLoS One, 2015, 10(10): e0139305. DOI: 10.1371/journal.pone.0139305. ［30］ Bernuzzi F, Marabita F, Lleo A, et al. Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma［J］. Clin Exp Immunol, 2016, 185(1): 61-71. DOI: 10.1111/cei.12776. ［31］ Shen J, Stass SA, Jiang F. MicroRNAs as potential biomarkers in human solid tumors［J］. Cancer Lett, 2013, 329(2): 125-136. DOI: 10.1016/j.canlet.2012.11.001. ［32］ Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review［J］. EMBO Mol Med, 2012, 4(3): 143159. DOI: 10.1002/emmm.201100209. ［33］ YáezMó M, Siljander PR, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions［J］. J Extracell Vesicles, 2015, 4: 27066. DOI: 10.3402/jev.v4.27066.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[3]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[4]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[5]	Chen Qi, Xu Chenyang, Wang Yin, Lei Dapeng. Current application status of hyperspectral imaging in the diagnosis and treatment of head and neck tumor [J]. Journal of International Oncology, 2024, 51(5): 298-302.
[6]	Zhang Lili, Tan Ru, Fang Xueli, Yang Yu, Sang Zheng, Li Baosheng. Imaging diagnosis， pathological upgrade， and imaging technology progress of ductal carcinoma in situ of the breast [J]. Journal of International Oncology, 2024, 51(3): 166-169.
[7]	Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185.
[8]	Gong Yan, Chen Honglei. Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer [J]. Journal of International Oncology, 2024, 51(3): 186-190.
[9]	Li Dan, Li Ruiyao, Li Yinghan, Yu Xiuyan, Wu Xuefeng. Clinical value of serum miR-19b and miR-744-5p levels in the diagnosis of non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(2): 83-88.
[10]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[11]	Huang Zhen, Chen Yongshun. Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma [J]. Journal of International Oncology, 2024, 51(1): 59-64.
[12]	Wang Jing, Xu Wenting. Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm [J]. Journal of International Oncology, 2023, 50(9): 520-526.
[13]	Huang Hui, Ding Jianghua. Advances in targeting FGFR2 for treatment of advanced cholangiocarcinoma [J]. Journal of International Oncology, 2023, 50(9): 569-573.
[14]	Shandong Medical Association Multidisciplinary Joint Committee on Lung Cancer. Shandong Provincial Medical Association multidisciplinary standardized diagnosis and treatment guidelines for esophageal carcinoma （2023 Edition） [J]. Journal of International Oncology, 2023, 50(7): 385-397.
[15]	Ju Yifan, Xu Chenyang, Lei Dapeng. Research progress of pathomics in head and neck neoplasms [J]. Journal of International Oncology, 2023, 50(5): 294-298.